Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit
Executives from Alumis (NASDAQ:ALMS) outlined recent clinical results, upcoming regulatory milestones, and pipeline priorities during a discussion at the Guggenheim Emerging Outlook Biotech Summit...